Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Safety, Reactogenicity, and Immunogenicity of Recombinant M2e Influenza-A Vaccine Candidate ACAM FLU-A) in Healthy Adults.

Next Previous
X
Search
Trial Profile

A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Safety, Reactogenicity, and Immunogenicity of Recombinant M2e Influenza-A Vaccine Candidate ACAM FLU-A) in Healthy Adults.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 19 Jan 2012

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ACAM-FLU-A (Primary) ; Aluminium hydroxide; QS 21
  • Indications Influenza A virus infections; Influenza virus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Acronyms FLU-A

    • Most Recent Events

    • 09 Jan 2009 ClinicalTrials.gov identified as an additional data source and information integrated.
    • 03 Jan 2008 Primary endpoint met; results reported in a Acambis media release.
    • 03 Jan 2008 Status changed from in progress to completed according to a media release from Acambis.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top